Edition:
India

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

5.20USD
11:09pm IST
Change (% chg)

$-0.09 (-1.61%)
Prev Close
$5.28
Open
$5.28
Day's High
$5.34
Day's Low
$5.08
Volume
101,724
Avg. Vol
243,562
52-wk High
$28.74
52-wk Low
$4.99

Latest Key Developments (Source: Significant Developments)

Diplomat Appoints Daniel Davison As CFO
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT APPOINTS DANIEL DAVISON AS CHIEF FINANCIAL OFFICER.DIPLOMAT PHARMACY INC - DAVISON SUCCEEDING ATUL KAVTHEKAR.DIPLOMAT PHARMACY - KAVTHEKAR WILL REMAIN WITH CO THROUGH BRIEF PERIOD TO ENSURE SMOOTH TRANSITION OF RESPONSIBILITIES.DIPLOMAT PHARMACY INC - DAVISON'S APPOINTMENT IS EFFECTIVE APRIL 8.  Full Article

Diplomat Pharmacy Inc Files For Non-Timely 10-K
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC FILES FOR NON-TIMELY 10-K- SEC FILING.DIPLOMAT PHARMACY - RECENTLY DETERMINED NEED TO RECORD SIGNIFICANT NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS.DIPLOMAT PHARMACY - SIGNIFICANT NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL, DEFINITE-LIVED INTANGIBLE ASSETS , WILL MATERIALLY IMPACT Q4 RESULTS.DIPLOMAT PHARMACY - NEEDS TIME TO FINALIZE LEVEL OF IMPAIRMENT FOR GOODWILL AND THE DEFINITE-LIVED INTANGIBLE ASSETS, TAX IMPLICATIONS, IMPACT ON Q4.  Full Article

Diplomat Delays Release Of 2018 Financial Results And Filing Of 10-K
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT DELAYS RELEASE OF 2018 FINANCIAL RESULTS AND FILING OF 10-K.DIPLOMAT PHARMACY INC - WILL PROVIDE UPDATED OUTLOOK WHEN IT REPORTS 2018 RESULTS..DIPLOMAT PHARMACY INC - COMPANY WITHDRAWS 2019 FULL YEAR PRELIMINARY OUTLOOK PROVIDED IN JANUARY.DIPLOMAT PHARMACY INC - COMPANY EXPECTS TO FILE ITS ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED DECEMBER 31, 2018 SOON AFTERWARDS..DIPLOMAT PHARMACY INC - WILL NEED TO RECORD A NON-CASH IMPAIRMENT CHARGE RELATED TO ITS PBM BUSINESS..DIPLOMAT PHARMACY INC - CHARGE IS EXPECTED TO BE EQUAL TO A SIGNIFICANT PORTION OF PBM'S GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS.DIPLOMAT PHARMACY INC - JANUARY RESULTS HAVE COME IN SIGNIFICANTLY BELOW EXPECTATIONS.DIPLOMAT PHARMACY - PBM'S GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS TOTALED ABOUT $630 MILLION AS OF DECEMBER 31, 2018, PRIOR TO IMPAIRMENT CHARGES.DIPLOMAT PHARMACY INC - NOTIFIED OF ADDITIONAL CUSTOMER LOSSES IN ITS PBM BUSINESS SINCE EARLY JANUARY.DIPLOMAT PHARMACY INC - CHARGE RELATES TO 2017 ACQUISITIONS OF NPS AND LDI AND IS DRIVEN BY REDUCED FINANCIAL FORECASTS FOR PBM BUSINESS..DIPLOMAT PHARMACY INC - FULL-YEAR 2018 REVENUES AND TOTAL ADJUSTED EBITDA ARE NOT IMPACTED BY ANY IMPAIRMENT CHARGE.DIPLOMAT PHARMACY INC - OBSERVING INCREASED COMPETITIVE PRESSURE IN SPECIALTY MARKET, DRIVING A REDUCED OUTLOOK FOR SCRIPT VOLUMES IN 2019.  Full Article

Diplomat Pharmacy Q2 Adjusted Earnings Per Share $0.17
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 2ND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.17.Q2 LOSS PER SHARE $0.05.Q2 REVENUE $1.416 BILLION VERSUS I/B/E/S VIEW $1.42 BILLION.SEES FY 2018 LOSS PER SHARE $0.15 TO $+0.01.SEES FY 2018 REVENUE $5.5 BILLION TO $5.9 BILLION.Q2 EARNINGS PER SHARE VIEW $0.23 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $0.92, REVENUE VIEW $5.67 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-GAAP ADJUSTED EPS $0.17.  Full Article

Diplomat Pharmacy Says Selling Shareholders To Sell Up To 4.1 Mln Shares Of Company
Saturday, 7 Apr 2018 

April 6 (Reuters) - Diplomat Pharmacy Inc ::SAYS SELLING SHAREHOLDERS TO SELL UP TO 4.1 MLN SHARES OF CO - SEC FILING.  Full Article

Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - ‍JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY​.DIPLOMAT PHARMACY INC - PHIL HAGERMAN TO CONTINUE SERVICE ON BOARD AND BECOME CHAIRMAN EMERITUS.DIPLOMAT PHARMACY INC - BOARD HAS APPOINTED BEN WOLIN, INDEPENDENT LEAD DIRECTOR, AS CHAIRMAN OF DIPLOMAT BOARD, EFFECTIVE IMMEDIATELY.DIPLOMAT INITIATES CEO TRANSITION; REAFFIRMS 2017 GUIDANCE AND PROVIDES PRELIMINARY 2018 OUTLOOK.DIPLOMAT PHARMACY - ‍PARK'S APPOINTMENT FOLLOWS RETIREMENT OF PHIL HAGERMAN.DIPLOMAT PHARMACY INC - IN 2018, DIPLOMAT PRELIMINARILY EXPECTS REVENUE IN RANGE OF $5.3 TO $5.6 BILLION.  Full Article

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::- EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE.FY2018 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S.DIPLOMAT REAFFIRMS 2017 GUIDANCE, PROVIDES PRELIMINARY 2018 OUTLOOK.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.- IN 2018, EXPECTS ADJUSTED EBITDA IN RANGE OF $164 TO $170 MILLION.  Full Article

Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES.DIPLOMAT PHARMACY INC - ENTERED INTO NEW $800 MILLION SENIOR SECURED CREDIT FACILITIES.DIPLOMAT PHARMACY - $800 MILLION FINANCING COMPRISED OF $250 MILLION REVOLVING CREDIT FACILITY, $150 MILLION TERM LOAN A FACILITY, $400 MILLION TERM LOAN B FACILITY.DIPLOMAT PHARMACY - PROCEEDS OF DEBT FINANCING WILL BE USED TO FINANCE LDI DEAL, REFINANCE DIPLOMAT'S CURRENT INDEBTEDNESS, AMONG OTHERS.  Full Article

Diplomat to acquire LDI Integrated Pharmacy Services
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Diplomat Pharmacy Inc :Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat Pharmacy Inc - ‍will pay LDI $515 million cash and approximately $80 million in diplomat common stock​.Diplomat Pharmacy Inc - ‍LDI is expected to generate approximately $388 million in revenue and $41 million in adjusted EBITDA in 2017​.Diplomat Pharmacy Inc - ‍cash portion of acquisition is expected to be funded by diplomat's new $795 million senior secured credit facility​.  Full Article

Diplomat Pharmacy announces 3rd quarter financial results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Diplomat Pharmacy Inc :Diplomat announces 3rd quarter financial results.Q3 adjusted earnings per share $0.25.Q3 earnings per share $0.01.Q3 revenue $1.125 billion versus I/B/E/S view $1.16 billion.Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $0.82 to $0.87.Sees FY 2017 earnings per share $0.15 to $0.20.Sees FY 2017 revenue $4.4 billion to $4.6 billion.FY2017 earnings per share view $0.75, revenue view $4.52 billion -- Thomson Reuters I/B/E/S.Diplomat Pharmacy Inc - ‍resolved arbitration with CVS and have transitioned from a PSAO contract to a direct contract with CVS​.  Full Article

UPDATE 1-Diplomat Pharmacy pulls 2019 forecast, delays results on charge

Feb 22 Diplomat Pharmacy Inc said on Friday it would withdraw its full-year forecast and delay its annual and fourth-quarter results after determining that it would need to record a charge related to its pharmacy benefits management (PBM) business.